Skip to main content
Fig. 3 | Molecular Brain

Fig. 3

From: Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation

Fig. 3

Immunoblot analysis of mTOR pathway activation by TSC2 mutants. a Representative immunoblot of S6K1 phosphorylation by novel frameshift TSC2 c.700–701 deletion (del) mutant expression. Note that the c.700–701 del mutant is detected as an approximately 37 kDa-sized band, whereas the wild-type TSC1 is detected as an approximately 200 kDa-sized band. b. Relative expression levels of TSC2 mutants in the presence of wild-type TSC1 (One-way ANOVA followed by Dunnett’s test, *** p <0.001). c Mean TSC1 expression levels in the presence of empty vector and TSC2 mutants relative to wild-type TSC2 (One-way ANOVA followed by Dunnett’s test, *** p <0.001). d Mean phospho-S6K levels generated by TSC2 variants’ expression relative to wild-type TSC1-TSC2 expression (One-way ANOVA followed by Dunnett’s test, * p <0.05). All data are shown as the mean ± SEM of nine independent experiments

Back to article page